Distinct molecular requirements for activation or stabilization of soluble guanylyl cyclase upon haem oxidation‐induced degradation
- 23 June 2009
- journal article
- Published by Wiley in British Journal of Pharmacology
- Vol. 157 (5), 781-795
- https://doi.org/10.1111/j.1476-5381.2009.00263.x
Abstract
In endothelial dysfunction, signalling by nitric oxide (NO) is impaired because of the oxidation and subsequent loss of the soluble guanylyl cyclase (sGC) haem. The sGC activator 4-[((4-carboxybutyl){2-[(4-phenethylbenzyl)oxy]phenethyl}amino)methyl[benzoic]acid (BAY 58-2667) is a haem-mimetic able to bind with high affinity to sGC when the native haem (the NO binding site) is removed and it also protects sGC from ubiquitin-triggered degradation. Here we investigate whether this protection is a unique feature of BAY 58-2667 or a general characteristic of haem-site ligands such as the haem-independent sGC activator 5-chloro-2-(5-chloro-thiophene-2-sulphonylamino-N-(4-(morpholine-4-sulphonyl)-phenyl)-benzamide sodium salt (HMR 1766), the haem-mimetic Zn-protoporphyrin IX (Zn-PPIX) or the haem-dependent sGC stimulator 5-cyclopropyl-2-[1-(2-fluoro-benzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]-pyrimidin-4-ylamine (BAY 41-2272). The sGC inhibitor 1H-(1,2,4)-oxadiazolo[4,3-a]quinoxalin-1-one (ODQ) was used to induce oxidation-induced degradation of sGC. Activity and protein levels of sGC were measured in a Chinese hamster ovary cell line as well as in primary porcine endothelial cells. Cells expressing mutant sGC were used to elucidate the molecular mechanism underlying the effects observed. Oxidation-induced sGC degradation was prevented by BAY 58-2667 and Zn-PPIX in both cell types. In contrast, the structurally unrelated sGC activator, HMR 1766, and the sGC stimulator, BAY 41-2272, did not protect. Similarly, the constitutively haem-free sGC mutant beta(1)H105F was stabilized by BAY 58-2667 and Zn-PPIX. The ability of BAY 58-2667 not only to activate but also to stabilize oxidized/haem-free sGC represents a unique example of bimodal target interaction and distinguishes this structural class from non-stabilizing sGC activators and sGC stimulators such as HMR 1766 and BAY 41-2272, respectively.Keywords
This publication has 49 references indexed in Scilit:
- Reactive oxygen species and the control of vascular functionAmerican Journal of Physiology-Heart and Circulatory Physiology, 2009
- Probing the presence of the ligand‐binding haem in cellular nitric oxide receptorsBritish Journal of Pharmacology, 2008
- Chaperone-dependent E3 ligase CHIP ubiquitinates and mediates proteasomal degradation of soluble guanylyl cyclaseAmerican Journal of Physiology-Heart and Circulatory Physiology, 2007
- Targeting Heme-Oxidized Soluble Guanylate CyclaseHypertension, 2007
- Fatal gastrointestinal obstruction and hypertension in mice lacking nitric oxide-sensitive guanylyl cyclaseProceedings of the National Academy of Sciences of the United States of America, 2007
- NO and CO differentially activate soluble guanylyl cyclase via a heme pivot-bend mechanismThe EMBO Journal, 2007
- Deconstructing endothelial dysfunction: soluble guanylyl cyclase oxidation and the NO resistance syndromeJCI Insight, 2006
- Targeting the heme-oxidized nitric oxide receptor for selective vasodilatation of diseased blood vesselsJCI Insight, 2006
- NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potentialNature Reviews Drug Discovery, 2006
- Spare guanylyl cyclase NO receptors ensure high NO sensitivity in the vascular systemJCI Insight, 2006